Bioniche Life Sciences Inc. 25 Years
Contact Us Careers
Home Newsroom
In the News

November 25, 2014
BIONICHE LIFE SCIENCES INC. REBRANDS AS TELESTA THERAPEUTICS INC.

November 13, 2014
Bioniche Life Sciences Inc. Announces Results of Annual General Meeting of Shareholders SHAREHOLDERS

Investors

Latest TSX stock price

All prices delayed at least 15 minutes.
Source: TSX Inc.


Fact Sheets/Backgrounders

About Urocidin™

What is Urocidin™?

Urocidin™ is a formulation of Mycobacterial Cell Wall-Nucleic Acid Complex, a sterile suspension of non-viable cell wall-nucleic acid composition prepared from a pure culture of Mycobacterium phlei (M. phlei). MCNA was formerly known as MCC, Mycobacterial Cell Wall-DNA Complex. It is currently being investigated for the treatment of non-muscle invasive bladder cancer (NMIBC) at high risk of recurrence or progression in patients who failed prior bacillus Calmette-Guérin (BCG) therapy.

MCNA - an immunotherapeutic biological product

Many anti-cancer drugs are synthetic or semi-synthetic chemical substances. In contrast, Mycobacterial Cell Wall-Nucleic Acid Complex (abbreviated to MCNA), is a biological product isolated from a pure culture of the saprophytic bacterium Mycobacterium phlei (M. phlei), found in soil, on plants, and in drinking water and not recognized as a pathogen for amphibians, birds, fish, or mammals. MCNA is a patented cell wall complex that has been fractioned and purified to optimize the presence of nucleic acids, which are responsible for a range of immunomodulatory and anti-cancer activities. It is formulated as a sterile, non-viable preparation, and thus cannot cause infections. MCNA is administrated by trans-urethral catheter directly into the bladder for the treatment of non-muscle invasive bladder cancer, where it can come in contact with cancer cells and with immune effector cells. MCNA was discovered by the Bioniche Life Sciences Inc. (Bioniche) research team from their studies on the composition of mycobacterial cell walls. Bioniche has developed and commercialized mycobacterial cell wall products as immunomodulatory drugs in the animal field for cancer and infectious diseases since the early 1980's.

MCNA - a dual mechanism of action

MCNA appears to exert its anti-cancer activity by a dual mechanism of action, i.e., with direct and indirect activities. MCNA appears to have a direct effect on cancer cells (chemotherapeutic-like activity) expressed as inhibition of cancer cell proliferation, induction of cell cycle arrest and induction of apoptosis. MCNA also appears to have an indirect, immune stimulant effect via the induction of cytokines known to participate in anticancer mechanisms. Nucleic acids associated with the cell wall, and originating from genomic DNA and RNA of M. phlei, appear to play a significant role in the expression of activity.

The proposed dual mechanism of action of MCNA is shown below (Figure 1).

Figure 1 - Mechanism of Action of MCNA

 

 

For further information:

William B. Wiederseim
President & CEO
PharmaBioSource, Inc.
Office: 610-293-0900
Cell: 610-888-9806
Email: wiederseim@pharmabiosource.com

Copyright 2004, Bioniche Life Sciences Inc. All rights reserved  |  Legal Disclaimer  |  Privacy Policy